{"id":"NCT00704353","sponsor":"American Regent, Inc.","briefTitle":"Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia","officialTitle":"A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2009-07","completion":"2011-03","firstPosted":"2008-06-24","resultsPosted":"2013-11-25","lastUpdate":"2018-02-20"},"enrollment":735,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose","otherNames":[]},{"type":"DRUG","name":"Standard Medical Care (SMC)","otherNames":["Ferrous Sulfate, Venofer, Ferrlecit, Infed, Dexferrum"]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Standard Medical Care","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Serious Adverse Events (SAE's)","timeFrame":"through 30 days after the last dose of study drug (FCM or SMC for the treatment of IDA)","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":5,"sd":null},{"arm":"Standard Medical Care","deltaMin":9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":366},"commonTop":[]}}